[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-sensitization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-sensitization":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601388","effect-of-boswellia-serrata-on-pain-intensity-central-and-peripheral-sensitization-and-pain-modulation-in-healthy-volunteers-100601388",false,"NCT07109843","Effect of Boswellia Serrata on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers","Effect of Boswellia Serrata on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers - a Randomized, Double-blind, Placebo-controlled, Cross-over Pilot Trial","BSPP","Inclusion Criteria:\n\n* Age: ≥18 years\n\nExclusion Criteria:\n\n* Not pregnant or breastfeeding\n* No renal or liver insufficiency\n* No neurological\u002Fdermatological\u002Fcardiovascular diseases\n* No chronic pain and\u002For use of analgesics\n* No use of anticoagulants\n* No use of antidepressants\n* No use of MAO inhibitors\n* No use of St. John's Wort\n* No use of medications affecting the CYP mechanism\n* No allergies to Boswellia serrata or capsaicin\"",true,"ALL","18 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","This planned study is based on a randomized, placebo-controlled cross-over design.\n\nBoswellic acids, the triterpenes found in the gum resins of Boswellia serrata (family: Burseraceae), are traditionally used in the Indian Ayurvedic medicine system as antioxidants and anti-inflammatory agents for treating conditions such as rheumatoid arthritis, chronic bronchitis, asthma, and chronic inflammatory bowel diseases (ulcerative colitis and Crohn's disease). The β-configured pentacyclic triterpenic acids in B. serrata include 3-acetyl-11-keto-β-boswellic acid (AKBBA), 11-keto-β-boswellic acid (KBBA), β-boswellic acid (BBA), and 3-acetyl-β-boswellic acid (ABBA). These compounds, which constitute approximately 14% of the lipophilic fractions of the B. serrata extract, are the major active components. Boswellia serrata is marketed as a food supplement in accordance with EU Directive 2002\u002F46\u002FEC. Several clinical studies have examined the efficacy of B. serrata in chronic pain conditions.\n\nThe data suggest a clinical analgesic efficacy, without, however, allowing conclusions about the underlying mechanisms. These have not yet been investigated in a human experimental pain model. The aim of the study is to investigate the influence of Boswellia serrata in peripheral and central sensitization, as well as descending inhibitory pathways by Quantitative Sensory Testing (QST). These findings are of great relevance for a better understanding of clinical efficacy.\n\nThe 'Capsaicin Pain Model' is a validated method for inducing short-term peripheral and central sensitization. As a non-invasive human pain model, it is therefore well suited for investigating the analgesic and anti-hyperalgesic effects of drugs.\n\nFurthermore, the influence of Boswellia serrata on mood (depression, anxiety), sleep quality and psychological well-being will be investigated by using the psychological questionnaires Becks-Depression-Inventory, Becks-Anxiety-Inventory, Pittsburgh Sleep Quality Index and World Health Organization Well-Being Index (BDI-II, BAI, PSQI and WHO5) as secondary target variables.",[28,29,30,31],"Chronic Pain","Central Sensitisation","Peripheral Sensitization","Neuroinflammatory Response","RECRUITING","2025-09-23",{"date":35,"type":36},"2025-09-24","ACTUAL",{"date":38,"type":36},"2025-09-01",{"date":40,"type":22},"2025-12-31",{"name":42,"class":43},"Medical University of Graz","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100584781","the-effect-of-griffonia-simplicifolia-on-pain-intensity-central-and-peripheral-sensitization-painmodulation-in-healthy-volunteers-100584781","NCT06893822","The Effect of Griffonia Simplicifolia on Pain Intensity, Central and Peripheral Sensitization, Painmodulation in Healthy Volunteers","The Effect of Griffonia Simplicifolia on Pain Intensity, Central and Peripheral Sensitization, Painmodulation in Healthy Volunteers - A Randomized, Double-blinded, Placebo-controlled, Cross-over Study","Exclusion Criteria:\n\n* pregnancy or breastfeeding.\n* renal or hepatic insufficiency\n* neurological\u002Fdermatological\u002Fcardiovascular diseases\n* chronic pain and\u002For use of analgesics\n* intake of antidepressants\n* intake of MAO inhibitors\n* intake of sleep medication\n* intake of St. John's wort\n* allergy to Griffonia simplicifolia","99 Years",{"count":54,"type":22},20,[25],"This planned study is based on a randomized, placebo-controlled cross-over design.\n\nGriffonia simplicifolia contains the serotonin-precursor 5-hydroxytryptophan (5-HTP), an endogenous amino acid. 5-HTP can cross the blood-brain barrier and is converted to serotonin. Low serotonin levels are associated with depression, anxiety disorders and sleep disorders, among others. Griffonia simplicifolia is marketed as a food supplement in accordance with EU Directive 2002\u002F46\u002FEC. Several clinical studies have examined the efficacy of 5-HTP in chronic pain conditions.\n\nThe data suggest a clinical analgesic efficacy, without, however, allowing conclusions about the underlying mechanisms. These have not yet been investigated in a human experimental pain model. The aim of the study is to investigate the influence of 5-HTP in peripheral and central sensitization, as well as descending inhibitory pathways by Quantitative Sensory Testing (QST). These findings are of great relevance for a better understanding of clinical efficacy.\n\nFor this purpose, \"repetitive phasic heat application\" is a validated method for achieving short-term peripheral and central sensitization. As a non-invasive human pain model, it is therefore well suited for investigating the analgesic and anti-hyperalgesic effects of drugs.\n\nFurthermore, the influence of Griffonia simplicifolia on mood (depression, anxiety), memory, sleep quality and psychological well-being will be investigated by using psychological questionnaires as secondary target variables.",[28,29,30,31],[59,60,61,29],"Griffonia simplicifolia","5-HTP","Peripheral Sensitisation","2025-06-12",{"date":64,"type":36},"2025-06-17",{"date":66,"type":22},"2025-09-12",{"date":68,"type":22},"2025-12-20",{"name":42,"class":43}]